1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antibody Drug Conjugate Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in clinical trial activities and robust product pipeline
5.1.1.3. Government support and initiatives encouraging research on cancer
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
5.1.3.2. Adoption of advanced technologies for developing ADC
5.1.4. Challenges
5.1.4.1. Complexity in manufacturing of ADCs
5.2. Market Segmentation Analysis
5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
5.3. Market Trend Analysis
5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Antibody Drug Conjugate Market, by Mechanism of Action
6.1. Introduction
6.2. CD30 Antibodies
6.3. ErbB2 Antibodies
7. Antibody Drug Conjugate Market, by Drugs
7.1. Introduction
7.2. Adcetris
7.3. Blenrep
7.4. Enhertu
7.5. Kadcyla
7.6. Padcev
7.7. Trodelvy
8. Antibody Drug Conjugate Market, by Technology
8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-Cleavable Linker
9. Antibody Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Lymphoma
9.5. Multiple Myeloma
9.6. Urothelial Cancer & Bladder Cancer
10. Antibody Drug Conjugate Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical & Biotechnology Companies
10.4. Hospitals
10.5. Specialized Cancer Centers
11. Americas Antibody Drug Conjugate Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Drug Conjugate Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Drug Conjugate Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Pyxis Oncology Successfully Completes Acquisition of Apexigen
14.3.1.2. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
14.3.1.3. Pfizer Invests USD 43 Billion to Battle Cancer
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
14.3.2.2. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
14.3.2.3. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
14.3.2.4. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
14.3.3. Investment & Funding
14.3.3.1. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
14.3.4. Award, Recognition, & Expansion
14.3.4.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
14.3.4.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
14.3.4.3. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. AbbVie Inc.
15.1.3. ADC Therapeutics SA
15.1.4. Ambrx Biopharma Inc.
15.1.5. Amgen Inc.
15.1.6. Astellas Pharma Inc.
15.1.7. AstraZeneca PLC
15.1.8. Bayer AG
15.1.9. BioNTech SE
15.1.10. Bristol-Myers Squibb Company
15.1.11. Byondis B.V.
15.1.12. Celldex Therapeutics Inc.
15.1.13. Creative Biolabs, Inc.
15.1.14. Daiichi Sankyo Company, Limited
15.1.15. Eisai Co., Ltd.
15.1.16. F. Hoffmann-La Roche Ltd.
15.1.17. Gilead Sciences, Inc.
15.1.18. GlaxoSmithKline PLC
15.1.19. Heidelberg Pharma AG
15.1.20. ImmunoGen, Inc.
15.1.21. Innate Pharma SA
15.1.22. Innovent Biologics, Inc.
15.1.23. Lonza Group Ltd.
15.1.24. MacroGenics, Inc.
15.1.25. MediLink Therapeutics
15.1.26. Merck KGaA
15.1.27. Mersana Therapeutics, Inc.
15.1.28. Novartis AG
15.1.29. Oxford Biotherapeutics Limited
15.1.30. Pfizer, Inc.
15.1.31. Pheon Therapeutics Ltd.
15.1.32. Piramal Pharma Limited
15.1.33. Recipharm AB
15.1.34. Sanofi S.A.
15.1.35. Sorrento Therapeutics, Inc.
15.1.36. Tagworks Pharmaceuticals BV
15.1.37. Takeda Pharmaceutical Company Limited
15.1.38. Tubulis GmbH
15.1.39. Zymeworks Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
